Limb-Girdle Muscular Dystrophy Type 1 – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Limb-Girdle Muscular Dystrophy Type 1 Market Outlook

Thelansis’s “Limb-Girdle Muscular Dystrophy Type 1  Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Limb-Girdle Muscular Dystrophy Type 1   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Limb-Girdle Muscular Dystrophy Type 1 Overview

Limb-Girdle Muscular Dystrophy Type 1 (LGMD1A, LGMD1B, LGMD1C, & Others (LGMD1D-H)) includes forms of the disorder that have an inheritance pattern called autosomal dominant. Majorly the LGMD1B comprises more than 65% of the total Limb-girdle muscular dystrophy type 1, followed by LGMD1C, LGMD1A, & Others type. The autosomal dominant forms of LGMD are less common than the autosomal recessive forms and appear later in life. In many cases, autosomal dominant LGMD progresses more slowly than autosomal recessive LGMD and has variable symptoms, even among members of the same family. Each gene mutation can cause a wide range of symptoms. LGMD1A can appear at any age, from adolescence to adulthood. This type of LGMD is distinguished by proximal muscle weakness, which is sometimes accompanied by slurred speech (dysarthria) and an abnormally tight Achilles tendon. LGMD1B causes proximal muscle weakness that gradually worsens. Affected individuals may also experience calf muscle hypertrophy and mild elbow or Achilles tendon contractures. LGMD1C is characterized by cramping muscle pain after exercise, mild to moderate proximal muscle weakness, and overgrowth of the calf muscle. LGMD1D-H short form is characterized by progressive muscle weakness that affects the hip-girdle area before spreading to the limb-girdle area.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Limb-Girdle Muscular Dystrophy Type 1   – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034